Talking the Cure: Discussing COVID-19’s impact on FDA’s inspection program and next steps after the pandemic

In this episode, Phil Katz and Jim Johnson continue their conversation about the impact of COVID-19 on FDA’s drug inspection program and the steps companies should take now and in preparation for when the pandemic is coming to an end. For all updates around COVID-19, visit our COVID-19 hub. You can find additional thought leadership and information regarding Medical Devices and Technology Regulatory on HL Engage. If you are interested in more information all around Life Sciences and Health Care, follow us on LinkedIn and Twitter.